Episode 219: ASCO GU 2023: Neeraj Agarwal, MD, FASCO Discusses the TALAPRO-2 study

Episode 219: ASCO GU 2023: Neeraj Agarwal, MD...

Up next

Episode 523: ESMO 2026: ctDNA Kinetics from Neoadjuvant EVP in MIBC

Jon Chatzkel joins us after his ESMO 2026 presentation to discuss ctDNA results from the KEYNOTE 905 trial. 

Episode 522: ESMO 2026 - KEYNOTE-905 Analysis of Neoadjuvant EVP or Pembro Monotherapy in Cis-ineligible MIBC

Anders Ullen joins the show after his EMSO 2026 presentation looking at KN-905 for the period in which Cis-ineligible MIBC patients were randomized to immediate cystectomy vs neoadjuvant Pembro or EVP. 

Recommended Episodes

Key Advances in Prostate, Kidney, and Bladder Cancers at GU24
ASCO Daily News

Drs. Neeraj Agarwal and Todd Morgan discuss CONTACT-02, KEYNOTE-564, CheckMate-67T, and other notable studies featured at the 2024 ASCO Genitourinary Cancers Symposium, as well as additional key abstracts in prostate, kidney, and bladder cancers that will significantly influen ...

  Show more

What's New in Prostate Cancer, RCC, and mUC at GU24
ASCO Daily News

Drs. Neeraj Agarwal and Jeanny Aragon-Ching discuss several key abstracts to be presented at the 2024 ASCO GU Cancers Symposium, including sequencing versus upfront combination therapies for mCRPC in the BRCAAway study, updates on the CheckMate-9ER and CheckMate-214 trials in ...

  Show more

Key Abstracts in GU Cancers at ASCO24
ASCO Daily News

Dr. Neeraj Agarwal and Dr. Jeanny Aragon-Ching discuss promising combination therapies and other compelling advances in genitourinary cancers in advance of the 2024 ASCO Annual Meeting.

<span style= "text-decoration: underline;">TRANSCRIPT</span>

  Show more